Ethylenedioxy-PIP2 oxalate reduces ganglioside storage in juvenile sandhoff disease mice

Neurochemical Research

Volumn 38, Issue 4, 2013, Pages 866-875

  Arthur, Julian R ^a   Wilson, Michael W ^b   Larsen, Scott D ^b   Rockwell, Hannah E ^a   Shayman, James A ^b,c   Seyfried, Thomas N ^a  

^a BOSTON COLLEGE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Ganglioside; Glycosphingolipid; Lysosomal storage disease; Neurodegeneration; Sandhoff disease; Substrate reduction therapy

Indexed keywords

2 (2,3 DIHYDRO 1H INDEN 2 YL) [1 (2,3 DIHYDROBENZO[B][1,4]DIOXIN 6 YL) 1 HYDROXY 3 (PYRROLIDIN 1 YL)PROPAN 2 YL]ACETAMIDE OXALATE; CCG 203586; CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; CHOLESTEROL; GANGLIOSIDE; GANGLIOSIDE GA2; GANGLIOSIDE GD 1A; GANGLIOSIDE GD 1B; GANGLIOSIDE GD3; GANGLIOSIDE GM1; GANGLIOSIDE GM2; GANGLIOSIDE GT 1B; GLUCOSYLCERAMIDE; PHOSPHOLIPID; SIALIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN WATER; BRAIN WEIGHT; CEREBELLUM; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; FEMALE; LIPID BRAIN LEVEL; LIPID STORAGE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SANDHOFF DISEASE;

ANIMALS; BRAIN; BRAIN CHEMISTRY; DIOXANES; GANGLIOSIDES; GLUCOSYLCERAMIDES; INDANS; MICE; SANDHOFF DISEASE;

MURINAE; MUS;

EID: 84876163453     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-013-0992-5     Document Type: Article

References (41)

1. Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057-2079 (Pubitemid 44879358)
2. Sango K, Yamanaka S, Hoffmann A et al (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 11:170-176
3. Phaneuf D, Wakamatsu N, Huang JQ et al (1996) Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 5:1-14 (Pubitemid 26018268)
4. Jeyakumar M, Butters TD, Dwek RA et al (2002) Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis. Neuropathol Appl Neurobiol 28:343-357 (Pubitemid 35279069)
5. Jeyakumar M, Thomas R, Elliot-Smith E et al (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126:974-987 (Pubitemid 36372994)
6. Kyrkanides S, Miller AW, Miller JN et al (2008) Peripheral blood mononuclear cell infiltration and neuroinflammation in the HexB-/- mouse model of neurodegeneration. J Neuroimmunol 203:50-57
7. Platt FM, Neises GR, Karlsson GB et al (1994) N- butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 269:27108-27114
8. Ichikawa S, Hirabayashi Y (1998) Glucosylceramide synthase and glycosphingolipid synthesis. Trends Cell Biol 8:198-202 (Pubitemid 28188114)
9. Baek RC, Kasperzyk JL, Platt FM et al (2008) N- butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice. Neurochem Int 52:1125-1133
10. Arthur JR, Lee JP, Snyder EY et al (2012) Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice. Neurochem Res 37:1335-1343
11. Platt FM, Neises GR, Reinkensmeier G et al (1997) Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science (New York, N.Y) 276:428-431 (Pubitemid 27180707)
12. Jeyakumar M, Butters TD, Cortina-Borja M et al (1999) Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 96:6388-6393 (Pubitemid 29256675)
13. Kasperzyk JL, d'Azzo A, Platt FM et al (2005) Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice. J Lipid Res 46:744-751 (Pubitemid 43073284)
14. Kasperzyk JL, El-Abbadi MM, Hauser EC et al (2004) N- butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis. J Neurochem 89:645-653 (Pubitemid 38534150)
15. Andersson U, Butters TD, Dwek RA et al (2000) N- butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo. Biochem Pharmacol 59:821-829 (Pubitemid 30081705)
16. Andersson U, Smith D, Jeyakumar M et al (2004) Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease. Neurobiol Dis 16:506-515 (Pubitemid 38942983)
17. Elliot-Smith E, Speak AO, Lloyd-Evans E et al (2008) Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol Genet Metab 94:204-211
18. Marshall J, Ashe KM, Bangari D et al (2010) Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE 5:e15033
19. Marshall J, McEachern KA, Chuang WL et al (2010) Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 33:281-289
20. Hollak CE, Hughes D, van Schaik IN et al (2009) Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf 18:770-777
21. Lukina E, Watman N, Arreguin EA et al (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116:893-899
22. Lukina E, Watman N, Arreguin EA et al (2010) Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116:4095-4098
23. Machaczka M, Hast R, Dahlman I et al (2012) Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution. Ups J Med Sci 117:28-34
24. Shayman JA (2010) ELIGLUSTAT TARTRATE: glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future 35:613-620
25. Cox TM, Aerts JM, Andria G et al (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26:513-526 (Pubitemid 37321530)
26. Cox TM (2010) Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs 11:1169-1181
27. Brumshtein B, Greenblatt HM, Butters TD et al (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282:29052-29058 (Pubitemid 47606022)
28. Alfonso P, Pampin S, Estrada J et al (2005) Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations. Blood Cells Mol Dis 35:268-276 (Pubitemid 41267059)
29. McEachern KA, Fung J, Komarnitsky S et al (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91:259-267 (Pubitemid 46819125)
30. Larsen SD, Wilson MW, Abe A et al (2012) Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain. J Lipid Res 53:282-291
31. Galjaard H (1979) Early diagnosis and prevention of genetic disease. Ann Clin Biochem 16:343-353 (Pubitemid 10105218)
32. Baek RC, Martin DR, Cox NR et al (2009) Comparative analysis of brain lipids in mice, cats, and humans with Sandhoff disease. Lipids 44:197-205
33. Hauser EC, Kasperzyk JL, d'Azzo A et al (2004) Inheritance of lysosomal acid beta-galactosidase activity and gangliosides in crosses of DBA/2J and knockout mice. Biochem Genet 42:241-257 (Pubitemid 39012266)
34. Macala LJ, Yu RK, Ando S (1983) Analysis of brain lipids by high performance thin-layer chromatography and densitometry. J Lipid Res 24:1243-1250 (Pubitemid 14236574)
35. Seyfried TN, Glaser GH, Yu RK (1979) Genetic variability for regional brain gangliosides in five strains of young mice. Biochem Genet 17:43-55 (Pubitemid 9158706)
36. Seyfried TN, Yu RK (1980) Heterosis for brain myelin content in mice. Biochem Genet 18:1229-1238 (Pubitemid 11156746)
37. Lee JP, Jeyakumar M, Gonzalez R et al (2007) Stem cells act through multiple mechanisms to benefit mice with neurodegenerative metabolic disease. Nat Med 13:439-447 (Pubitemid 46559825)
38. Denny CA, Heinecke KA, Kim YP et al (2010) Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice. J Neurochem 113:1525-1535
39. Ashe KM, Bangari D, Li L et al (2011) Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease. PLoS ONE 6:e21758
40. Brigande JV, Platt FM, Seyfried TN (1998) Inhibition of glycosphingolipid biosynthesis does not impair growth or morphogenesis of the postimplantation mouse embryo. J Neurochem 70:871-882 (Pubitemid 28079380)
41. Platt FM, Neises GR, Dwek RA et al (1994) N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269:8362-8365